Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 10/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24437016 | 0.95 | CMA1 (0.38) | CMA1KDM5AADORA3ADORA2AADORA1 | |
| SCHEMBL22016873 | 0.80 | AAK1 (0.39) | CMA1KDM5AADORA3ADORA2AADORA1 | |
| SCHEMBL22016877 | 0.78 | ADORA3 (0.41) | CMA1KDM5AADORA3ADORA2AADORA1 | |
| SCHEMBL22016876 | 0.77 | AAK1 (0.40) | CMA1KDM5AADORA3ADORA2AADORA1 | |
| SCHEMBL22016197 | 0.76 | ADORA3 (0.42) | CMA1KDM5AADORA3ADORA2AADORA1 | |
| SCHEMBL22017691 | 0.67 | GRM4 (0.44) | CMA1ADORA3ADORA2AADORA1 | |
| SCHEMBL22016239 | 0.66 | ADORA3 (0.43) | CMA1KDM5AADORA3ADORA2AADORA1 | |
| SCHEMBL24984421 | 0.65 | ASAH1 (0.35) | CNR1CNR2 | |
| SCHEMBL22035451 | 0.65 | ADORA3 (0.40) | CMA1KDM5AADORA3ADORA2AADORA1 | |
| SCHEMBL26597430 | 0.65 | TDP1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | CMA1 146/4885KDM5A 2386/4885ADORA3 1752/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | CMA1 146/4885KDM5A 2386/4885ADORA3 1752/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | CMA1 146/4885KDM5A 2386/4885ADORA3 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.